Canada ATMA receives Health Canada approval for new psilocybin trial Study will evaluate psilocybin efficacy in healthcare workers with mental health challenges related to pandemic Rowan DunneSeptember 15, 2022
International PharmAla Biotech to provide University of Sydney with LaNeo MDMA for clinical studies Organization to supply GMP product for second major clinical trial down under this month Rowan DunneAugust 31, 2022
Psychedelics MindMed announces initial patient dosing in MM-120 study Biopharmaceutical company administers optimized form of LSD in Phase 2b dose-optimization trial Rowan DunneAugust 25, 2022
International Mind Medicine Australia receives AUD$1M grant for psychedelic research New fund will support studies on psychedelic-assisted therapies for the treatment of mental health conditions Rowan DunneAugust 23, 2022
Cannabis Tilray receives approval for CBD oral solution in Australia and New Zealand Flagship product from company's medical cannabis division now set for clinical trial use Rowan DunneAugust 23, 2022
Research Lobe Sciences partners with iNGENū for new clinical trials in Australia Canadian biopharmaceutical company will receive government tax incentive for studies down under Rowan DunneAugust 12, 2022
Medical and Pharmaceutical Natera and RenaCARE aim for early detection of kidney disease Natera (NASDAQ:NTRA) acquired full enrolment for the RenaCARE (Renasight Clinical Application, Review and Evaluation) study, which is a prospective, multi-center clinical trial to determine... Joseph MortonAugust 11, 2022
Health & Wellness EverythingALS and NeuroSense take aim at Lou Gehrig’s disease ALS affects up to 30,000 people in the United States with 5,000 new cases every year, according to John Hopkins Medicine. Joseph MortonAugust 2, 2022
Medical and Pharmaceutical Context Therapeutics and Menarini Group put together clinical trial for breast cancer drug Breast cancer is the second most common cancer among women. Joseph MortonAugust 2, 2022
Cannabis US DEA suggests big increase of cannabis and psilocybin production for research The agency says it supports research into the substances and it's necessary for the FDA to approve new quotas Kathryn TindaleSeptember 1, 2021